1Lawes CM, Vander Hoorn S & Rodgers A (2008) International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 371, 1513–1518.
2Collins R, Peto R, MacMahon S, et al. (1990) Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335, 827–838.
3MacMahon S, Peto R, Cutler J, et al. (1990) Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335, 765–774.
4Collins R & MacMahon S (1994) Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 50, 272–298.
5Prospective Studies Collaboration (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903–1913.
6Cook NR, Cohen J, Hebert PR, et al. (1995) Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 155, 701–709.
7Stamler J (1997) The INTERSALT Study: background, methods, findings, and implications. Am J Clin Nutr 65, 626S–642S.
8Houston MC (2007) Treatment of hypertension with nutraceuticals, vitamins, antioxidants and minerals. Expert Rev Cardiovasc Ther 5, 681–691.
9Thomas GN, Cheung BM, Ho SY, et al. (2007) Overview of dietary influences on atherosclerotic vascular disease: epidemiology and prevention. Cardiovasc Hematol Disord Drug Targets 7, 87–97.
10Rudkowska I & Jones PJ (2007) Functional foods for the prevention and treatment of cardiovascular diseases: cholesterol and beyond. Expert Rev Cardiovasc Ther 5, 477–490.
11Murray BA & FitzGerald RJ (2007) Angiotensin converting enzyme inhibitory peptides derived from food proteins: biochemistry, bioactivity and production. Curr Pharm Des 13, 773–791.
12FitzGerald RJ & Meisel H (2000) Milk protein-derived peptide inhibitors of angiotensin-I-converting enzyme. Br J Nutr 84, Suppl. 1, S33–S37.
13FitzGerald RJ, Murray BA & Walsh DJ (2004) Hypotensive peptides from milk proteins. J Nutr 134, 980S–988S.
14Lopez-Fandino R, Otte J & van Camp J (2006) Physiological, chemical and technological aspects of milk-protein-derived peptides with antihypertensive and ACE-inhibitory activity. Int Dairy J 16, 1277–1293.
15Jauhiainen T & Korpela R (2007) Milk peptides and blood pressure. J Nutr 137, 825S–829S.
16Seppo L, Kerojoki O, Suomalainen T, et al. (2002) The effect of a Lactobacillus helveticus LBK-16H fermented milk on hypertension – a pilot study on humans. Milchwissenschaft 57, 124–127.
17Seppo L, Jauhiainen T, Poussa T, et al. (2003) A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am J Clin Nutr 77, 326–330.
18Sano J, Ohki K, Higuchi T, et al. (2005) Effect of casein hydrolysate, prepared with protease derived from Aspergillus oryzae, on subjects with high-normal blood pressure or mild hypertension. J Med Food 8, 423–430.
19Sano J, Ohki K, Higuchi T, et al. (2005) Safety evaluation of excessive intake of drink containing ‘lactotripeptides (VPP, IPP)’ in subjects with normal blood pressure to mild hypertension. J Nutr Food 7, 17–30.
20Mizuno S, Matsuura K, Gotou T, et al. (2005) Antihypertensive effect of casein hydrolysate in a placebo-controlled study in subjects with high-normal blood pressure and mild hypertension. Br J Nutr 94, 84–91.
21Itakura H, Ikemoto S, Terada S, et al. (2001) The effect of sour milk on blood pressure in untreated hypertensive and normotensive subjects. J Jap Soc Clin Nutr 23, 26–31.
22Kajimoto O, Aihara K, Hirata H, Takahashi R & Nakamura Y (2001) Hypotensive effects of the tablets containing ‘lactotripeptides (VPP, IPP)’. J Nutr Food 4, 51–61.
23Kajimoto O, Kurosaki T, Mizutani J, et al. (2002) Antihypertensive effects of liquid yogurts containing ‘lactotripeptides (VPP, IPP)’ in mild hypertensive subjects. J Nutr Food 5, 55–66.
24Hirata H, Nakamura Y, Yada H, et al. (2002) Clinical effects of new sour milk drink on mild or moderate hypertensive subjects. J New Rem Clin 51, 61–69.
25Aihara K, Kajimoto O, Hirata H, et al. (2005) Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension. J Am Coll Nutr 24, 257–265.
26Kajimoto O, Nakamura Y, Yada H, et al. (2001) Hypotensive effects of sour milk in subjects with mild or moderate hypertension. J Jpn Soc Nutr Food Sci 54, 347–354.
27Nakamura Y, Kajimoto O, Kaneko K, et al. (2004) Effects of the liquid yogurts containing ‘lactotripeptide (VPP, IPP)’ on high-normal blood pressure. J Nutr Food 7, 123–137.
28Brown CD, Higgins M, Donato KA, et al. (2000) Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 8, 605–619.
29Burke GL, Bertoni AG, Shea S, et al. (2008) The impact of obesity on cardiovascular disease risk factors and subclinical vascular disease: the Multi-Ethnic Study of Atherosclerosis. Arch Intern Med 12, 928–935.
30Reckelhoff JF (2001) Gender differences in the regulation of blood pressure. Hypertension 37, 1199–1208.
31Jauhiainen T, Vapaatalo H, Poussa T, et al. (2005) Lactobacillus helveticus fermented milk lowers blood pressure in hypertensive subjects in 24-h ambulatory blood pressure measurement. Am J Hypertens 18, 1600–1605.
32World Health Organization, International Society of Hypertension Writing Group (2003) 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21, 1983–1992.
33Yasuda K, Aihara K, Komazaki K, et al. (2001) Effect of large high intake of tablets containing ‘lactotripeptides (VPP, IPP)’ on blood pressure, pulse rate and clinical parameters in healthy volunteers. J Nutr Food 4, 63–72.
34Law MR, Wald NJ, Morris JK, et al. (2003) Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J 326, 1427–1431.
35Mizushima S, Ohshige K, Watanabe J, et al. (2004) Randomized controlled trial of sour milk on blood pressure in borderline hypertensive men. Am J Hypertens 17, 701–706.
36Hata Y, Yamamoto M, Ohni M, et al. (1996) A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. Am J Clin Nutr 64, 767–771.
37Kearney PM, Whelton M, Reynolds K, et al. (2005) Global burden of hypertension: analysis of worldwide data. Lancet 365, 217–223.
38Tuomilehto J, Lindstrom J, Hyyrynen J, et al. (2004) Effect of ingesting sour milk fermented using Lactobacillus helveticus bacteria producing tripeptides on blood pressure in subjects with mild hypertension. J Hum Hypertens 18, 795–802.
39Anderson PJ, Critchley JA, Tomlinson B, et al. (1995) Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers. Br J Clin Pharmacol 39, 361–368.
40Anderson PJ, Critchley JA & Tomlinson B (1996) A comparison of the pharmacokinetics and pharmacodynamics of cilazapril between Chinese and Caucasian healthy, normotensive volunteers. Eur J Clin Pharmacol 50, 57–62.
41Vaidyanathan S, Jermany J, Yeh C, et al. (2006) Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol 62, 690–698.
42Japanese Ministry of Health, Labour and Welfare (2004) The National Nutrition Survey in Japan, 2002. Tokyo: Ministry of Health, Labour and Welfare.
43Nakamura Y, Yamamoto N, Sakai K, et al. (1995) Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J Dairy Sci 78, 777–783.
44Masuda O, Nakamura Y & Takano T (1996) Antihypertensive peptides are present in aorta after oral administration of sour milk containing these peptides to spontaneously hypertensive rats. J Nutr 126, 3063–3068.
45Sipola M, Finckenberg P, Korpela R, et al. (2002) Effect of long-term intake of milk products on blood pressure in hypertensive rats. J Dairy Res 69, 103–111.
46Nurminen M, Sipola M, Kaarto H, et al. (2000) α-Lactorphin lowers blood pressure via radiotelemetry in normotensive and spontaneously hypertensive rats. Life Sci 66, 1535–1543.
47Maes W, Van Camp J, Vermeirssen V, et al. (2004) Influence of the lactokinin Ala-Leu-Pro-Met-His-Ile-Arg (ALPMHIR) on the release of endothelin-1 by endothelial cells. Regul Pept 118, 105–109.
48Hirota T, Ohki K, Kawagishi R, et al. (2007) Casein hydrolysate containing the antihypertensive tripeptides Val-Pro-Pro and Ile-Pro-Pro improves vascular endothelial function independent of blood pressure-lowering effects: contribution of the inhibitory action of angiotensin-converting enzyme. Hypertens Res 30, 489–496.
49Vermeirssen V, Van Camp J & Verstraete W (2004) Bioavailability of angiotensin I converting enzyme inhibitory peptides. Br J Nutr 92, 357–366.
50Foltz M, Meynen EE, Bianco V, et al. (2007) Angiotensin converting enzyme inhibitory peptides from a lactotripeptide-enriched milk beverage are absorbed intact into the circulation. J Nutr 137, 953–958.
51Engberink MF, Schouten EG, Kok FJ, et al. (2008) Lactotripeptides show no effect on human blood pressure: results from a double-blind randomized controlled trial. Hypertension 51, 399–405.
52Allender PS, Cutler JA, Follmann D, et al. (1996) Dietary calcium and blood pressure: a meta-analysis of randomized controlled trials. Ann Intern Med 124, 825–831.
53Griffith LE, Guyatt GH, Cook RJ, et al. (1999) The influence of dietary and nondietary calcium supplementation on blood pressure: an updated meta-analysis of randomized controlled trials. Am J Hypertens 12, 84–92.
54Jee SH, Miller ER III, Guallar E, et al. (2002) The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. Am J Hypertens 15, 691–696.
55van Mierlo LA, Arends LR, Streppel MT, et al. (2006) Blood pressure response to calcium supplementation: a meta-analysis of randomized controlled trials. J Hum Hypertens 20, 571–580.
56Linas SL (1991) The role of potassium in the pathogenesis and treatment of hypertension. Kidney Int 39, 771–786.
57Whelton PK, He J, Cutler JA, et al. (1997) Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 277, 1624–1632.
58Elliott P, Kesteloot H, Appel LJ, et al. (2008) INTERMAP Cooperative Research Group. Dietary phosphorus and blood pressure: international study of macro- and micro-nutrients and blood pressure. Hypertension 51, 669–675.
59Grimble GK (1994) The significance of peptides in clinical nutrition. Annu Rev Nutr 14, 419–447.
61Bernard BK, Nakamura Y, Bando I, et al. (2005) Studies of the toxicological potential of tripeptides (l-valyl-l-prolyl-l-proline and l-isoleucyl-l-prolyI-l-proline): II. Introduction. Int J Toxicol 24, Suppl. 4, 5–11.
62Dent MP, O'Hagan S, Braun WH, et al. (2007) A 90-day subchronic toxicity study and reproductive toxicity studies on ACE-inhibition of lactotripeptide. Food Chem Toxicol 45, 1468–1477.
63Kajimoto O, Aihara K, Hirata H, et al. (2001) Safety evaluation of excessive intake of the tablet containing ‘Lactotripeptides (VPP, IPP)’ on healthy volunteers. J Nutr Food 4, 37–46.